CGEN (CGEN) Stock Price & Analysis
CGEN (CGEN) fell 2.56% to USD 2.28 as of July 25, 2026 at 08:05 UTC, according to Nexqual real-time market data.
CGEN last closed at USD 2.34; the session ranged USD 2.26–2.38 on volume of 200,063 shares. Market capitalization is $215.65M, with a 52-week range of USD 1.3–3.24 (NCM). Source: Nexqual, July 25, 2026 at 08:05 UTC.
Key Statistics (as of July 25, 2026 at 08:05 UTC)
| Price | USD 2.28 |
|---|---|
| Change | ▼ 2.56% (down) |
| Previous Close | USD 2.34 |
| Open | USD 2.34 |
| Day Range | USD 2.26 – 2.38 |
| 52-Week Range | USD 1.3 – 3.24 |
| Volume | 200,063 shares |
| Market Cap | $215.65M |
| Exchange | NCM |
Technical Analysis (CGEN)
Nexqual's technical model rates CGEN "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 08:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.62 (neutral) |
| vs SMA50 | Below (USD 2.34) |
| MACD | 0.03 (positive) |
Analyst Ratings (CGEN)
Wall Street analysts rate CGEN "Strong Buy" based on 5 analysts, with a mean price target of USD 4.6 (range USD 4–6), per Nexqual as of July 25, 2026 at 08:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.6 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (CGEN)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $1.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-12-31 | USD 0.6 vs est 0.14 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.09 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Financials & Fundamentals (CGEN)
| Total Revenue | $72.66M |
|---|---|
| Revenue Growth (YoY) | -4.70% |
| Gross Margin | +88.06% |
| Operating Margin | -414.38% |
| Profit Margin | +47.97% |
| ROE | +45.72% |
| Debt / Equity | 3.08 |
| Current Ratio | 6.23 |
| Total Cash | $134.95M |
| Total Debt | $2.93M |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Financial Health Score (CGEN)
Nexqual rates CGEN's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 08:05 UTC.
| Growth | Strong — Revenue +161% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $135M cash vs $3M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 46%, ROA 14.7% |
Ownership (CGEN)
| Insider Ownership | +2.08% |
|---|---|
| Institutional Ownership | +15.42% |
| Shares Outstanding | 94.58M |
| Float | 92.42M |
| Short % of Float | +3.20% |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Leadership (CGEN)
CGEN is led by Eran Ophir (age 47), CEO, President & Director, per Nexqual as of July 25, 2026 at 08:05 UTC.
| CEO, President & Director | Eran Ophir (age 47) |
|---|---|
| Chief Operating Officer | Pierre Ferre (age 48) |
| Senior Vice President of Business Development | Zurit Levine (age 57) |
| Chief Financial Officer | David Silberman (age 41) |
| Vice President of Human Resources | Dorit Amitay (age 57) |
Major Backers & Investors (CGEN)
Notable institutional backers of CGEN include SilverArc Capital Management, LLC, ARK Invest, Renaissance Technologies, according to Nexqual as of July 25, 2026 at 08:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SilverArc Capital Management, LLC | 3.55% |
| ARK Invest | 1.96% |
| Renaissance Technologies | 1.75% |
| Morgan Stanley | 1.13% |
| Nomura Asset Management International Inc | 1.09% |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 1.09% |
| Taylor Frigon Capital Management LLC | 0.9% |
| Two Sigma Investments, LP | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 0.88% |
| Northern Trust | 0.7% |
Source: Nexqual, July 25, 2026 at 08:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CERS | Cerus Corporation | USD 2.93 | ▼ 2.98% |
| SYRS | Syros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| MCRB | Seres Therapeutics, Inc. | USD 4.97 | ▼ 5.97% |
| EVGN | Evogene Ltd. | USD 0.54 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:05 UTC. This page is informational and not investment advice.